Neuronetics publishes investor presentation on NeuroStar TMS, Greenbrook clinic network strategy
STIM•Investor presentation outlines FY 2026 guidance and second-quarter results
- Neuronetics outlined FY 2026 revenue guidance of USD 160 million to USD 164 million, implying 7% to 10% year-on-year growth.
- Gross margin outlook set at 48% to 50%.
- Operating expenses projected at USD 91 million to USD 96 million, excluding about USD 4 million of non-cash stock-based compensation.
- Cash flow from operations and investing forecast at negative USD 10.5 million to negative USD 14.5 million.
- Second-quarter revenue reported at USD 41.57 million, up 9% year-on-year; adjusted EBITDA turned positive at USD 0.25 million.
